172 351

Cited 124 times in

Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.

 S. Park  ;  J. S. Koo  ;  M. S. Kim  ;  H. S. Park  ;  J. S. Lee  ;  J. S. Lee  ;  S. I. Kim  ;  B.-W. Park  ;  K. S. Lee 
 ANNALS OF ONCOLOGY, Vol.22(8) : 1755-1762, 2011 
Journal Title
Issue Date
Adult ; Biomarkers, Tumor/metabolism* ; Breast Neoplasms/metabolism* ; Breast Neoplasms/mortality* ; Breast Neoplasms/pathology ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Middle Aged ; Receptor, ErbB-2/metabolism ; Receptors, Androgen/metabolism* ; Receptors, Estrogen/metabolism ; Tissue Array Analysis ; Treatment Outcome
androgen receptor ; breast cancer ; estrogen receptor ; molecular apocrine ; prognosis
BACKGROUND: The objective of the study was to evaluate the implications of androgen receptor (AR) in breast cancers. PATIENTS AND METHODS: We investigated immunohistochemical AR expression from the tissue microarrays of 931 patients between 1999 and 2005, and analyzed demographics and outcomes using uni-/multivariate analyses. Tumors with ≥10% nuclear-stained cells were considered positive for AR. RESULTS: AR was expressed in 58.1% of patients. AR was significantly related to older age at diagnosis, smaller size, well-differentiated tumors, higher positivity of hormone receptors, non-triple-negative breast cancers (non-TNBCs), and lower proliferative index. In estrogen receptor (ER)-negative tumors, AR was distinctively associated with human epidermal growth factor receptor type 2 (HER2) overexpression. With a mean follow-up of 72.7 months, AR was positively related to survival in ER-positive but not in ER-negative tumors. In Cox's models, AR was an independent prognostic factor for disease-free survival in ER-positive cancers. Interestingly, molecular apocrine tumors (ER negative and AR positive) with HER2 positive status showed trends of poorer outcome, but AR had no impact on survival in patients with TNBC. CONCLUSIONS: AR is significantly associated with favorable features in breast cancers and related to better outcomes in ER-positive not in ER-negative tumors. These results suggest that AR could be an additional marker for endocrine responsiveness in ER-positive cancers and a candidate for therapeutic targeting of ER-negative tumors.
Files in This Item:
T201102652.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Koo, Ja Seung(구자승) ORCID logo https://orcid.org/0000-0003-4546-4709
Kim, Seung Il(김승일)
Park, Byeong Woo(박병우) ORCID logo https://orcid.org/0000-0003-1353-2607
Park, Se Ho(박세호) ORCID logo https://orcid.org/0000-0001-8089-2755
Park, Hyung Seok(박형석) ORCID logo https://orcid.org/0000-0001-5322-6036
Lee, Jong Seok(이종석)
Lee, Jun Sang(이준상) ORCID logo https://orcid.org/0000-0002-4054-6900
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.